09:54 AM EST - Valeant Pharmaceuticals International, Inc. : announced that its wholly-owned subsidiary, Valeant Canada Limited, has received notice that the New Drug Submission for Sublinox has been approved from the Canadian regulatory authority Health Canada. Sublinox (zolpidem tartrate) is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $0.71 at $52.88.
